Psychiatry and Neurology, Neurology · Orange, CA
NPI
1821438805
Since 2013
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
101 the City Dr S
Orange, CA, 92868
Phone (714) 880-7812
Groups this clinician bills Medicare through
Medicare paid, 2024
$98K
1,251 services
Medicare patients, 2024
381
Average age 73
Drug cost, 2024
$1.1M
2,786 prescriptions
Company payments, 2025
$7,876
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sanaz Attaripour-Isfahani was code 99215 (office e&m - established), 373 times for 219 patients. In total Sanaz Attaripour-Isfahani billed 1,251 services in 31 codes, and Medicare paid $98K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-10-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 373 | 219 | $119.18 | $44K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 192 | 117 | $14.36 | $2,757 |
| 99205 Office E&M - New | Office | 74 | 74 | $146.49 | $11K |
| 99215 Office E&M - Established | Facility | 59 | 41 | $117.56 | $6,936 |
| 99214 Office E&M - Established | Office | 58 | 48 | $82.64 | $4,793 |
| 99213 Office E&M - Established | Office | 49 | 33 | $52.96 | $2,595 |
| 11105 Skin Biopsy | Office | 46 | 22 | $21.32 | $981 |
| 95874 Musculoskeletal | Office | 43 | 19 | $17.44 | $750 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 27 | 21 | $14.78 | $399 |
| 64616 Musculoskeletal | Office | 25 | 11 | $82.33 | $2,058 |
| 11104 Skin Biopsy | Office | 23 | 22 | $38.20 | $879 |
| 64642 Musculoskeletal | Office | 21 | 11 | $77.44 | $1,626 |
| 99214 Office E&M - Established | Facility | 16 | 14 | $70.62 | $1,130 |
By year: 2022 $99K for 3,532 services; 2023 $91K for 1,019 services; 2024 $98K for 1,251 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sanaz Attaripour-Isfahani prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 614 prescriptions and refills. In total Sanaz Attaripour-Isfahani wrote 2,786 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 614 | 1,401 | 165 | $18K |
| Gabapentin Generic | 230 | 483 | 65 | $3,741 |
| Donepezil Hcl Generic | 168 | 400 | 51 | $2,306 |
| Clonazepam Generic | 132 | 163 | 33 | $693 |
| Amantadine Amantadine Hcl | 111 | 230 | 31 | $6,628 |
| Rytary Carbidopa/Levodopa | 105 | 193 | 20 | $82K |
| Rasagiline Mesylate Generic | 103 | 222 | 32 | $30K |
| Primidone Generic | 78 | 192 | 21 | $3,660 |
| Neupro Rotigotine | 75 | 127 | 18 | $112K |
| Linzess Linaclotide | 57 | 94 | 16 | $49K |
| Nuplazid Pimavanserin Tartrate | 53 | 73 | Under 11 | $337K |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 48 | 122 | 16 | $960 |
| Emgality Pen Galcanezumab-Gnlm | 48 | 48 | Under 11 | $33K |
| Ropinirole Hcl Generic | 45 | 79 | 13 | $1,271 |
| Levetiracetam Generic | 43 | 102 | Under 11 | $2,816 |
Brand drugs: - claims; generic drugs: 2,289 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sanaz Attaripour-Isfahani $7,876 ($7,876 in general payments such as food, travel and fees) from 3 companies. The largest payer was Abbvie Inc. with $5,761.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.